Avotaciclib trihydrochloride(Synonyms: BEY1107 trihydrochloride)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Avotaciclib trihydrochloride (Synonyms: BEY1107 trihydrochloride)

Avotaciclib (BEY1107) trihydrochloride 是一种有效和具有口服活性的 cyclin dependent kinase 1 (CDK1) 抑制剂。Avotaciclib trihydrochloride 可用于局部晚期或转移性胰腺癌的研究。

Avotaciclib trihydrochloride(Synonyms: BEY1107 trihydrochloride)

Avotaciclib trihydrochloride Chemical Structure

CAS No. : 1983984-01-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Avotaciclib (BEY1107) trihydrochloride is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). Avotaciclib trihydrochloride can be used for the research of locally advanced or metastatic pancreatic cancer[1].

IC50 & Target[1]

CDK1

 

分子量

390.66

Formula

C13H14Cl3N7O
CAS 号

1983984-01-5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Seufferlein T, et, al. Phase I Trials in Pancreatic Cancer. Translational Pancreatic Cancer Research pp 219-232.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务